A BURTON-based pharmaceutical company could be set to create new jobs after revealing that revenue had grown by nearly 50 per cent.
The Clinigen Group, based on the Centrum 100 business park, saw revenue increase to £122.6 million since it floated on the stock market last year.
Profits before tax stood at £20.4 million — up 29 per cent — during the past year.
Chief executive Peter George said: “We have over delivered on our commitments made at the time of the flotation last September.
“In turn, the listing has lived up to our expectations.
“It has provided a stronger platform from which to drive our organic growth, both in the UK and internationally, as well as giving us additional financial flexibility to support our acquisition plans and the acceleration of our international growth strategy.
“It has also enabled greater investment in the infrastructure and recruitment of additional high-quality people to the business.”
The Clinigen Group formed in 2010 and now has offices in Burton, the USA and Japan.
The company is planning to expand its presence in Burton and could create up to 90 new jobs in the town during the next few years.
Mr George added: “Our ambition for the next financial year is to maintain this momentum.
“Geographically, we are focusing our attention on the US, Latin America and Asia.
“With a sound financial base, an increasing international footprint, as well as the recent organisational changes, we have the right foundations to continue the scale-up of the business and maintain our growth.”
Clinigen was floated on the AIM stock exchange, the London Stock Exchange’s international market for smaller growing companies, last September..
The firm is made up of three parts – Clinigen’s CTS division, which supplies services for clinical trials to test unlicensed medicines; the SP division, which sells medicines for use in fields such as pain management, cancer treatment and critical care; and the GAP division, which manages programmes to deliver medicines and products across the entire world.